サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541189

非メラノーマ皮膚がん治療市場レポート：治療タイプ、適応症、最終用途、地域別、2024年～2032年

Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 144 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
非メラノーマ皮膚がん治療市場レポート：治療タイプ、適応症、最終用途、地域別、2024年～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

非メラノーマ皮膚がん治療市場の世界市場規模は、2023年に5億6,320万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに8億5,010万米ドルに達し、2024年から2032年の間に4.5％の成長率（CAGR）を示すと予測しています。

非メラノーマ皮膚がん（NMSC）とは、皮膚の上層部における悪性細胞の異常増殖を指します。NMSCの一般的なタイプには、基底細胞がん、メルクル細胞がん、扁平上皮がん、皮膚T細胞リンパ腫などがあります。主に、皮膚に硬いしこりやうろこ状の斑点ができるのが特徴です。治療手法としては、顕微鏡手術、レーザー治療、凍結療法などの外科的処置によるがん細胞の除去や、光線力学的療法（PDT）、放射線治療、電気治療などのさまざまな非外科的治療があります。

皮膚がんの有病率の増加と、世界の老人人口の増加が、市場の成長を促進する主な要因となっています。さらに、NMSCに対する利用可能な代替治療法に関する大衆の意識の高まりも、市場成長を刺激しています。従来から使用されている治療法と比較すると、表在性放射線療法は患者の体への副作用が少なく、革新的なポータブル機器を使って実施することができます。また、これらの機器は高い精度と感度で皮膚病変の早期診断にも使用されています。さらに、電子ブラキセラピー（eBx）の開発など、さまざまな技術の進歩も成長を促す要因として作用しています。eBxは痛みのない非侵襲的な標的低エネルギー放射線療法であり、治療期間が短く、近隣の健康な組織への放射線被曝のリスクを最小限に抑えることができます。その他の要因として、個人のヘルスケア支出の増加、臨床試験に対する政府からの資金援助、広範な研究開発（R&D）活動などが市場をさらに牽引すると予想されます。

本レポートで扱う主な質問

  • 世界の非メラノーマ皮膚がん治療市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19は世界の非メラノーマ皮膚がん治療市場にどのような影響を与えたか？
  • 主要地域市場とは？
  • 治療タイプ別の市場内訳は？
  • 適応症別の市場内訳は？
  • 最終用途に基づく市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主な促進要因と課題は何か？
  • 世界の非メラノーマ皮膚がん治療市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の非メラノーマ皮膚がん治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 化学療法
    • 市場動向
    • 市場予測
  • 放射線治療
    • 市場動向
    • 市場予測
  • 光線力学療法
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：適応症別

  • 基底細胞がん
    • 市場動向
    • 市場予測
  • T細胞リンパ腫
    • 市場動向
    • 市場予測
  • 扁平上皮がん
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：最終用途別

  • 病院
    • 市場動向
    • 市場予測
  • 専門クリニック
    • 市場動向
    • 市場予測
  • 外来手術センター
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Accuray Incorporated
    • Almirall S.A.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Elekta AB
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Icad Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Varian Medical Systems Inc.
図表

List of Figures

  • Figure 1: Global: Non-Melanoma Skin Cancer Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by End Use (in %), 2023
  • Figure 6: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 8: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Non-Melanoma Skin Cancer Treatment Industry: SWOT Analysis
  • Figure 82: Global: Non-Melanoma Skin Cancer Treatment Industry: Value Chain Analysis
  • Figure 83: Global: Non-Melanoma Skin Cancer Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Melanoma Skin Cancer Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 5: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Non-Melanoma Skin Cancer Treatment Market Structure
  • Table 7: Global: Non-Melanoma Skin Cancer Treatment Market: Key Players
目次
Product Code: SR112024A3438

The global non-melanoma skin cancer treatment market size reached US$ 563.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 850.1 Million by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.

Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-melanoma skin cancer treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, indication and end use.

Breakup by Treatment Type:

Chemotherapy

Radiation Therapy

Photodynamic Therapy

Others

Breakup by Indication:

Basal Cell Carcinoma

T-Cell Lymphoma

Squamous Cell Carcinoma

Others

Breakup by End Use:

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.

Key Questions Answered in This Report:

  • How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Melanoma Skin Cancer Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Photodynamic Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Basal Cell Carcinoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 T-Cell Lymphoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Squamous Cell Carcinoma
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Accuray Incorporated
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Almirall S.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Elekta AB
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Eli Lilly and Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Icad Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sun Pharmaceutical Industries Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Varian Medical Systems Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis